Last reviewed 2026-04-22 · How we verify

Met IR

Met IR is a formulation of metformin immediate-release that reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes.

Met IR is a formulation of metformin immediate-release that reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and improving peripheral glucose uptake and utilization. The immediate-release formulation allows for rapid absorption and onset of action compared to extended-release formulations. It does not stimulate insulin secretion, making it suitable for use across a range of glycemic control states.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
• Metallic taste
• Vitamin B12 deficiency
• Lactic acidosis (rare)

Key clinical trials

• Strain Counterstrain and Muscle Energy Technique in Patients of Knee Osteoarthritis (NA)
• Stratified Pharmacological Approaches for Regulating Circuit-Level Effects (PHASE2)
• EMDR Versus Imagery Rescripting for Trauma-Related Intrusions (NA)
• Infrared LED Lighting Application and Wound Healing (NA)
• Screening of Endovascular Thrombectomy With MRI in Acute Ischemic Stroke
• Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer (PHASE2)
• Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis (PHASE3)
• The Impact of the Distribution of Adipose Tissue on the Occurrence of Metabolic Disorders and the Level of Cardiopulmonary Fitness

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.